Participated · Series B · Mar 2026

Crossbow Therapeutics is developing a portfolio of T-Bolt™ T-cell engager (TCE) therapies built from T-cell receptor-mimetic antibodies that target peptide–HLA (pHLA) complexes on cancer cells. Its lead program, CBX-250, is a first-in-class TCE targeting a pHLA specific to myeloid cancer cells and is being evaluated in the ongoing CROSSCHECK-001 Phase 1 trial in relapsed and refractory myeloid malignancies. The company is advancing CBX-663, a TCE targeting a TERT-derived pHLA, toward IND submission and a planned Phase 1 start in Q3 2026 for multiple hematologic and solid tumors. Crossbow positions its T-Bolt™ platform as broadly adaptable to address intracellular cancer targets previously unreachable by antibodies. The company will present preclinical data for both programs at the AACR 2026 Annual Meeting and expects initial clinical data from CBX-250 around the end of 2026. The recent $77 million Series B is intended to fund completion of CBX-250’s Phase 1 and to accelerate initiation and development of additional T-Bolt™ programs.

Participated · Series A · May 2025

HAYA Therapeutics develops programmable, RNA-guided therapies that target regulatory long non-coding RNAs to reprogram pathological cell states. Its core product approach maps and decodes the regulatory genome using multimodal functional genomics and proprietary computational and machine-learning methods. The company’s lead candidate, HTX-001, is a first-in-class lncRNA-targeting therapy in development for heart failure, initially focused on non-obstructive hypertrophic cardiomyopathy (nHCM). HAYA plans to initiate clinical trials for HTX-001 and to expand its pipeline across pulmonary fibrosis, obesity and other age-related and chronic diseases. The company has also formed strategic collaborations, including a partnership with Eli Lilly focused on RNA-based targets for obesity and metabolic disorders. HAYA is headquartered at the Biopôle life sciences park in Lausanne, Switzerland, with laboratory facilities in San Diego. HAYA Therapeutics develops programmable RNA-guided regulatory genome targeting therapeutics that act on long non-coding RNAs (lncRNAs) to reprogram pathological cell states. Its lead candidate, HTX-001, is in development for the treatment of heart failure, and the company is advancing a pipeline of lncRNA-targeting precision therapies for other tissues and indications. HAYA positions its platform to address rare, common, chronic and age-associated diseases and is extending its work into oncology. The company received an Innosuisse Certificate for Sustainable Growth and 1.5M CHF (approximately $1.64M USD) in non-dilutive funding to support translational studies over the next two years. Those funds will be used to develop a therapy targeting cancer-associated fibroblast-specific lncRNA for aggressive solid tumors. HAYA is headquartered at Biopôle in Lausanne, Switzerland, and maintains laboratory facilities at JLABS @ San Diego. HAYA Therapeutics develops a proprietary regulatory genome discovery platform that identifies tissue-, disease- and cell-specific long non-coding RNA (lncRNA) targets and enables RNA-targeting therapies. The platform is positioned to reprogram disease-driving cell states with the aim of delivering therapies that may have better efficacy and less toxicity than current treatments. HAYA is applying this full-stack platform to discovery and validation of lncRNA targets for obesity and related metabolic disorders. Under a multi-year collaboration with Eli Lilly, the partners will identify, characterize, and validate multiple regulatory genome-derived RNA-based drug targets. The company will receive an upfront payment that includes an equity investment and stands to earn milestone payments and royalties if programs progress. HAYA’s immediate plans center on preclinical drug discovery work within the collaboration to generate candidate targets and advance them toward development. HAYA Therapeutics is a Biopôle-based Swiss startup developing precision medicines and lncRNA-targeting anti-fibrotics using its proprietary DiscoverHAYA drug discovery engine. The company has established a new laboratory at JLABS @ San Diego while maintaining its main headquarters and laboratory facilities in Lausanne. HAYA will use the new funding to grow its team in Switzerland and San Diego and to advance its lead therapeutic candidate that targets a driver of cardiac fibrosis. The lead therapy is being developed to treat non-obstructive hypertrophic cardiomyopathy, an orphan indication with limited treatment options. Financially, HAYA closed a $5 million seed extension that brings the total seed financing to approximately $25 million. HAYA Therapeutics develops precision genomic medicines that target tissue- and cell-specific long non-coding RNAs (lncRNAs) to prevent and reverse fibrosis and other age-related conditions. Its proprietary DiscoverHAYA™ drug discovery engine generates a pipeline of lncRNA-targeting anti-fibrotics for organs including heart, lung, kidney, liver and the tumor microenvironment. The lead program is an antisense oligonucleotide targeting the cardiac-enriched lncRNA Wisper, which in preclinical studies at Lausanne University Hospital demonstrated the ability to halt and potentially reverse cardiac fibrosis. HAYA secured an exclusive license from CHUV for the Wisper asset and is preparing to initiate clinical trials in non-obstructive hypertrophic cardiomyopathy. The company is headquartered at the Biopôle life sciences park in Lausanne, Switzerland and is led by a team of lncRNA and fibrosis experts. The CHF 18 million seed financing will be used to advance discovery and development of its organ- and cell-selective therapeutic programs.

Participated · Series A · Oct 2024

Arda Therapeutics develops targeted cell depletion therapies that identify and selectively eliminate pathogenic cells via a single-cell-based discovery engine. Its platform detects disease-driving cells and their surface markers to enable targeted biologics that spare healthy tissue. The company positions this approach as applicable across fibrotic conditions (including pulmonary fibrosis), autoimmune and metabolic disorders. Arda aims to progress lead programs toward the clinic and expand its platform to additional disease areas. The company recently appointed Scott Turner, Ph.D., as chief scientific officer to advance fibrosis and biomarker strategies. Arda announced a $43 million Series A to fund clinical progression and platform expansion.

Participated · Series A · Oct 2022

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases using deep phenotyping, precision RNA medicine, and testing in live human donor livers. The company has generated spatial‑sequencing, single‑cell sequencing, and imaging data in over 1,000 diseased human livers across three continents. Ochre has launched 'Liver ICUs' across the US to test RNA‑based drug candidates directly in human livers. Proceeds from the Series A will be used to translate discovery research into RNA drug candidates and to fund human liver preclinical testing in 2023 to select therapies for clinical development in 2024. The company plans to broaden its discovery and development platforms, including a state‑of‑the‑art RNA chemistry platform and an exploratory platform to expand research into a wider set of liver diseases. Ochre's longer‑term goals include regenerating organs in patients and improving the viability of marginal donor livers to reduce the need for transplants. Ochre Bio develops RNA medicines for chronic liver diseases and uses deep phenotyping ('phenomics') to digitize liver biology at scale. The company has generated large amounts of spatial genomics data from freshly donated human livers and uncovered hundreds of novel potential liver targets that are being validated in their labs. By 2022, Ochre plans to build a complete in silico human liver of over 10^11 measurements to predict the effect of perturbing any gene in major liver cell types. In addition to computational work, Ochre tests therapeutics in explanted human livers maintained extracorporeally and has developed a full-stack GalNAc-siRNA development process validated in actively perfused human livers. Planned uses of recent funding include advancing RNA therapies, expanding the deep phenotyping platform, onboarding five transplant center partners to test therapies on discarded donor livers, and moving products toward clinical development; the company also opened a Taiwanese lab to study liver disease in Asia. Ochre is based in Oxford, England and is built on over 15 years of experience in liver genomics and advanced therapies.